Zimmer Biomet Holdings (ZBH) Tops Q4 EPS by 5c, Beats on Revenue; Offers FY23 Guidance

Zimmer Biomet Holdings (NYSE: ZBH) reported Q4 EPS of $1.88, $0.05 better than the analyst estimate of $1.83. Revenue for the quarter came in at $1.83 billion versus the consensus estimate of $1.76 billion.

GUIDANCE:

Zimmer Biomet Holdings sees FY2023 EPS of $6.95-$7.15, versus the consensus of $6.98.

For earnings history and earnings-related data on Zimmer Biomet Holdings (ZBH) click here.

You May Also Be Interested In

• IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance
• Netskope, Inc. (NTSK) Tops Q1 EPS by 1c, Offers Guidance
• Broadcom (AVGO) Tops Q2 EPS by 5c, Offers Guidance